Table 1.
The association between PD-L1 status and clinical-pathological characteristics.
| PD-L1 | P | ||
| Positive (N = 57) | Negative (N = 40) | ||
| Age, median (IQR)∗ | 61.0 (14.0) | 63.0 (15.0) | .531 |
| Sex, N (%) | .116 | ||
| Male | 44 (77.2) | 25 (62.5) | |
| Female | 13 (22.8) | 15 (37.5) | |
| Pathological type, n (%) | .005 | ||
| Adenocarcinoma | 35 (61.4) | 35 (87.5) | |
| Squamous cell carcinoma | 22 (38.6) | 5 (12.5) | |
| Tumor size, median (IQR)∗ | 3.5 (4.0) | 2.0 (1.9) | <.001 |
| Nerve invasion | .007 | ||
| No | 42 (73.7) | 38 (95.0) | |
| Yes | 15 (26.3) | 2 (5.0) | |
| Blood vessel invasion | .006 | ||
| No | 30 (52.6) | 32 (80.0) | |
| Yes | 27 (47.4) | 8 (20.0) | |
| Lymph node metastasis | <.001 | ||
| No | 20 (35.1) | 29 (72.5) | |
| Yes | 37 (64.9) | 11 (27.5) | |
| Stage∗ | <.001 | ||
| I | 14 (24.6) | 22 (55.0) | |
| II | 8 (14.0) | 10 (25.0) | |
| III + IV | 35 (61.4) | 8 (20.0) | |